Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Positive Topline Data Available on A3907 for Cholestatic Liver Diseases

    In a news release from mid-December 2021, rare liver disease company Albireo Pharma, Inc. ("Albireo") shared that positive topline data was available from a Phase 1 clinical trial evaluating A3907…

    Continue Reading Positive Topline Data Available on A3907 for Cholestatic Liver Diseases
    HINT1 Mutations Cause Neuromyotonia in Greek Patients with CMT
    source: pixabay.com

    HINT1 Mutations Cause Neuromyotonia in Greek Patients with CMT

    According to Charcot-Marie-Tooth News, researchers have associated HINT1 gene mutations with neuropathy in Greek patients with Charcot-Marie-Tooth disease (CMT). In the past, HINT1 was linked to CMT in central and southeastern Europe. However, researchers…

    Continue Reading HINT1 Mutations Cause Neuromyotonia in Greek Patients with CMT
    New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma
    https://unsplash.com/photos/tV-RX0beDp8

    New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma

    In a recent news release, biopharmaceutical companies AbbVie, Inc. and SpringWorks Therapeutics, Inc. ("SpringWorks") shared that the two had entered into a joint clinical trial collaboration agreement. Through this collaboration,…

    Continue Reading New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma
    First Subject Dosed in Laquinimod Trial for Uveitis
    Source: https://unsplash.com/photos/6F2mPewg2RA

    First Subject Dosed in Laquinimod Trial for Uveitis

    On December 10, 2021, biotechnology company Active Biotech shared that the first subject was dosed within a Phase 1 clinical trial evaluating laquinimod for non-infectious non-anterior uveitis. What is particularly…

    Continue Reading First Subject Dosed in Laquinimod Trial for Uveitis